INHIBRX BIOSCIENCES, INC. (INBX) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $176.28M.
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $174.99M.
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $100.56M.
- 2025-09-30: Long-term Debt, Excluding Current MaturitiesUSD $99.92M.
INHIBRX BIOSCIENCES, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD |
|---|---|
| 2026-06-30 | $176.28M |
| 2026-03-31 | $174.99M |
| 2025-12-31 | $100.56M |
| 2025-09-30 | $99.92M |
| 2025-06-30 | $99.28M |
| 2025-03-31 | $98.65M |
| 2024-12-31 | $0.00 |
| 2024-09-30 | $0.00 |
| 2024-06-30 | $0.00 |
| 2023-12-31 | $206.97M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |